Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07188441 | Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. | recruiting | Phase 2 | 40 | Chengcheng GuoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07109401 |
| Perioperative Immunotherapy for Resectable Limited-Stage SCLC |
| recruiting |
| Phase 2 |
| 37 |
| Fudan UniversityOTHER |
| 1 |
| Aug 7, 2025 |
| clinicaltrials |
| NCT04268121 | Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas(NEONEC) | recruiting | Phase 2 | 78 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04837885 | Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases(LUTARTERIAL) | recruiting | Phase 2 | 23 | University Hospital, BordeauxOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06395402 | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry(LUMOD-ID) | recruiting | Phase 2 | 120 | University of IowaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05173246 | JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05623319 | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)(THOR) | recruiting | Phase 2 | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04952480 | Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer(DARTS) | recruiting | Phase 2 | 31 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06455358 | 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) | recruiting | Phase 1 / Phase 2 | 27 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06911606 | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 45 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06056362 | Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 80 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05165407 | Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)(NESSIE) | recruiting | Phase 2 | 30 | Peking UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06663098 | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).(CARRY-ON) | recruiting | Phase 2 | 142 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06855095 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial(ATSA) | recruiting | Phase 2 / Phase 3 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06769971 | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | recruiting | Phase 2 | 80 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06749691 | Liposomal Irinotecan and Apatinib in ES-SCLC(LIAES) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06440057 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 78 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT02185443 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases | recruiting | Phase 2 | 43 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04917484 | Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients(DOBATOC) | recruiting | Phase 2 | 100 | Tine Gregersen, MDOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06698965 | Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05554003 | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study(MeTe) | recruiting | Phase 2 | 46 | European Institute of OncologyOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04166006 | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.(RaC-Ad) | recruiting | Phase 2 | 51 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06527898 | Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06562920 | Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer(Neoadjuvant) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC(LUFOR) | recruiting | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06393816 | FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum(FIRST-NEC) | recruiting | Phase 2 | 80 | Centre Leon BerardOTHER | 2 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | recruiting | Phase 2 | 96 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06485544 | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | recruiting | Phase 2 | 104 | Tang-Du HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06472388 | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors(EVENET) | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06110572 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation(TESSERACT) | recruiting | Phase 1 / Phase 2 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04893785 | A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)(CABOTEM) | recruiting | Phase 2 | 35 | National Cancer Institute, NaplesOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06464068 | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA(DURVASCC) | recruiting | Phase 2 | 66 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06371482 | Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) | recruiting | Phase 2 | 58 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06256237 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | recruiting | Phase 2 | 30 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06418087 | Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)(DUPLE) | recruiting | Phase 2 | 49 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06070740 | First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | recruiting | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Sep 23, 2025source: clinicaltrials